1. American Heart Association: 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association, 2002.
2. Abdallah MH, Arnaout S, Karrowni W, Dakik HA. The management of acute myocardial infarction in developing countries. Int J Cardiol 2006; 111: 189–94.
3. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators: Inhibition of the plat-let glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med 1998; 338: 1488–97.
4. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502.
5. Fragmin and Fast Revascularisation during Instability in Coronary Artery Disease (FRISC II) Investigators: Invasive compared with noninvasive treatment in unstable coronary-artery disease: FRISC II prospective randomized multicenter study. Lancet 1999; 354: 708–15.
6. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879–87.
7. de Winter RJ, Windhausen F, Cornel JH et al. Early invasive versus selectively invasive management of acute coronary syndromes. N Engl J Med 2005; 353: 1095–104.
8. Shephard MDS, Hester J, Walmsley RN, White GN. Variation in plasma apolipoprotein A-I and B concentrations following myocardial infarction. Ann Clin Biochem 1990; 27: 9–14.
9. Ollson AG, Schwartz GG, Szarek M et al. High-density lipoprotein, but not low-density lipoprotein cholesterol influence short-term prognosis after acute coronary syndrome: results from the MIRACLE trial. Eur Heart J 2005; 26: 890–6.
10. Gordon T, Castelli WP, Hjortland MC et al. High-density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62: 707–14.
11. Stenestrand U, Wallentin L. For Swedish Register of Cardiac Intensive Care (RIKS-HIA): Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430–6.
12. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA 2001; 85: 1711–8.
13. de Lemos JA, Blazing MA, Wiviott SD et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307–16.
14. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–504.
15. Schwartz GG, Olsson AG, Szarek M, Sasiela WJ. Characteristics of metabolic syndrome: relation to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome. An analysis of the MIRACL trial. Diabetes Care 2005; 28: 2508–13.
16. Olsson AG, Schwartz GG, Szarek M et al. Effects of high-dose atorvastatin in patients ≥65 years of age with acute coronary syndrome. Am J Cardiol 2007; 99: 632–5.
17. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–59.
18. Kinlay S, Schwartz GG, Olsson AG et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003; 108: 1560–6.
19. Tsimikas S, Witztum JL, Miller ER et al. High-dose atorvastatin reduces plasma levels of oxidized LDL in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004; 110: 1406–12.
20. Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20–8.
21. Kleeman R, Verschuren L, de Rooij BJ et al. Evidence of atiinflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 2004; 103: 4188–94.
22. Voleti B, Agrawal A. Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist. Mol Immunol 2006; 43: 891–6.
23. Verma S, Yeh ETH. C-reactive protein and atherotrombosis – Beyond a biomarker: an actual partaker of lesion formation. Am J Physiol Regul Integr Comp Physiol 2003; 285: R1253–R1256.
24. La Rosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–35.
25. Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437–45.
26. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720–32.

В.О.Константинов, Г.А.Кухарчик, А.В.Кузнецов, Я.Р.Павлова, Н.Б.Калишевич

Медицинская академия им. И.И.Менчинкова, Центр профилактики и лечения атеросклероза, Санкт-Петербург